Triple Combination Therapy in Hypertension: The Antihypertensive Efficacy of Treatment with Perindopril, Amlodipine, and Indapamide SR

The blood pressure (BP) of most patients on antihypertensive monotherapy or bitherapy remains uncontrolled. Our study evaluated the efficacy of triple therapy with perindopril, amlodipine, and indapamide sustained release (SR) in patients with uncontrolled hypertension on previous antihypertensive therapy. This 4-month, multicenter, prospective, observational, open-label study included patients switched from previous antihypertensive therapy to triple therapy with perindopril, amlodipine, and indapamide SR. The main outcome was change in office BP from baseline to 4 months, as well as changes in 24-h ambulatory BP monitoring (ABPM) parameters in a subgroup of patients. Age was 62.8 +/- A 11.3 years in 6,088 patients (55 % were male). Office BP at baseline was 158.1 +/- A 13.0/92.6 +/- A 8.8 mmHg. By 4 months, office BP decreased by 26.7 +/- A 13.3/12.9 +/- A 9.4 mmHg (p < 0.001). ABPM was performed in 62 patients. In these patients, 24-h systolic BP decreased (from 138.7 +/- A 12.5 to 125.5 +/- A 12.8 mmHg), as did 24-h diastolic BP (from 77.5 +/- A 11.4 to 70.4 +/- A 8.7 mmHg) (both p < 0.0001). Heart rate remained unchanged. In patients previously on renin-angiotensin-aldosterone system (RAAS) inhibitor/amlodipine, 24-h ambulatory systolic and diastolic BP decreased from 136.9 +/- A 12.8 to 125.4 +/- A 13.3 mmHg (p = 0.0003) and from 76.3 +/- A 12.6 to 70.2 +/- A 9.5 mmHg (p = 0.0005). In those previously on RAAS inhibitor/hydrochlorothiazide, 24-h ambulatory systolic and diastolic BP decreased from 137.8 +/- A 12.7 to 122.7 +/- A 15.4 mmHg (p = 0.0039) and from 73.6 +/- A 9.4 to 65.7 +/- A 7.3 mmHg (p = 0.002). Most (74 and 80 %, respectively) patients reached target ABPM values (< 130/80 mmHg). A triple combination of perindopril, amlodipine, and indapamide SR controlled BP effectively in hypertensive patients uncontrolled by previous antihypertensive monotherapy or bitherapy, including RAAS inhibitor/amlodipine or RAAS inhibitor/hydrochlorothiazide combinations.